In a groundbreaking study published just last week, researchers from the Shenzhen Institutes of Advanced Technology at the Chinese Academy of Sciences (CAS) have uncovered a novel "liver-bone marrow adipose tissue-cartilage" axis that drives the pathological process of osteoarthritis (OA). This discovery, detailed in the journal Bone Research, challenges traditional views of OA as merely a local joint wear-and-tear condition and positions it as a systemic disease influenced by multi-organ interactions. Led by Researcher Min Guan, the team demonstrates how metabolic stress in aging or obesity triggers bone marrow adipose tissue (MAT) expansion, fueling complement system overactivation that ultimately damages cartilage cells.
Osteoarthritis, the most common form of arthritis, affects cartilage—the flexible tissue cushioning joint ends—leading to pain, stiffness, and reduced mobility. While previously attributed mainly to mechanical stress and aging, this research highlights metabolic and inflammatory crosstalk between distant organs, opening doors to new therapeutic targets.
🦴 The Growing Burden of Osteoarthritis in China
China faces one of the world's heaviest OA burdens, with prevalence rates soaring amid rapid aging and urbanization. According to Global Burden of Disease data, OA cases in China exceeded 130 million by 2021, with age-standardized prevalence rates climbing steadily. Projections indicate continued rises, particularly for knee OA, the most debilitating form, imposing massive economic strain—estimated at billions in healthcare costs and lost productivity annually.
In urban areas like Shenzhen, lifestyle factors such as high-fat diets and sedentary habits exacerbate metabolic dysfunction, a key trigger identified in this CAS study. Elderly populations, projected to comprise 30% of China's total by 2030, are hit hardest, underscoring the urgency for innovative research from institutions like SIAT-CAS.
Unraveling the "Liver-MAT-Cartilage" Axis: Step-by-Step Mechanism
The core innovation lies in linking liver steatosis (fatty liver), MAT expansion in bones, and cartilage breakdown via the complement system—a part of innate immunity that clears pathogens but turns destructive here. Here's how it unfolds:
- Step 1: Metabolic Stress Triggers MAT Expansion. In aging or high-fat/high-cholesterol diets, bone marrow adipocytes proliferate abnormally, regulated by estrogen-related receptor alpha (ESRRA), a nuclear receptor sensing metabolic stress.
- Step 2: ESRRA Upregulates CFD. ESRRA binds directly to the promoter of the complement factor D (CFD) gene in adipocytes, boosting its transcription and secretion. CFD is the rate-limiting enzyme in the alternative complement pathway.
- Step 3: Liver Contributes C3. Steatotic livers overproduce complement component 3 (C3), the pathway's substrate.
- Step 4: C3-CFD Synergy Forms MAC. MAT-derived CFD cleaves C3, amplifying activation and assembling the membrane attack complex (MAC) on chondrocyte surfaces.
- Step 5: Chondrocyte Damage. MAC triggers ERK1/2 signaling, causing mitochondrial dysfunction, cellular senescence (aging), apoptosis (cell death), and extracellular matrix (ECM) degradation—hallmarks of OA pathology.
This inter-organelle crosstalk explains why systemic metabolic issues manifest as joint destruction, validated in mouse models of natural aging and diet-induced OA.
Experimental Evidence from CAS Labs
Using adipocyte-specific ESRRA knockout mice, the team observed suppressed MAT growth and milder OA symptoms: less cartilage loss, reduced subchondral bone sclerosis, and minimal synovial inflammation. Micro-CT scans and OARSI scoring confirmed joint preservation.
In human chondrocytes (C28/I2 cells), blocking ESRRA or CFD prevented MAC-induced damage, highlighting translational potential.
Photo by Chester Alvarez on Unsplash
Promising Interventions: From Bench to Bedside
The study proposes targeting ESRRA/CFD as therapeutics:
- Andrographolide: A natural ESRRA antagonist from traditional Chinese medicine (Andrographis paniculata), orally administered to aged mice for 3 months, halted cartilage degeneration without affecting body weight.
- Danicopan: A CFD inhibitor in clinical trials for other conditions, protected human chondrocytes from inflammatory stress.
These weight-independent strategies could benefit obese or elderly patients, where current treatments like painkillers or joint replacements fall short. Read the full paper in Bone Research for detailed methodologies and data.
CAS's Role in Pioneering OA Research
The Chinese Academy of Sciences, through institutes like SIAT, leads global OA efforts. Collaborations with Shenzhen University, Soochow University, and international partners like the University of Hong Kong amplify impact. This builds on prior CAS work, such as gut-joint axes and semaglutide's metabolic benefits in OA.
Funding from National Key R&D Programs underscores China's investment in biomedicine, positioning SIAT as a hub for degenerative disease research.
Stakeholder Perspectives: Clinicians, Patients, and Industry
Orthopedic experts hail the multi-organ view as paradigm-shifting, potentially reducing reliance on invasive surgeries. Patients, facing lifelong pain management, welcome non-surgical options rooted in traditional remedies like andrographolide.
Pharma interest surges around ESRRA modulators, with implications for metabolic syndrome comorbidities.
Challenges and Future Directions
- Translating mouse findings to humans requires Phase I trials for andrographolide.
- Biomarkers for MAT-CFD activity to enable early diagnosis.
- Integrating with AI for personalized OA risk prediction, leveraging CAS's computational strengths.
Longitudinal studies in diverse Chinese populations will validate generalizability.
Global Context and China's Leadership
While Western research focuses on cartilage regeneration, CAS emphasizes systemic metabolism—in line with China's aging crisis. This axis complements gut microbiome links, painting OA as a whole-body disorder.
CAS press release details collaborations.
Actionable Insights for Researchers and Clinicians
Aspire to CAS-level impact? Explore /research-jobs for similar roles. Monitor ESRRA inhibitors' trials via clinical registries.
